Enzon to Present at Cowen 27th Annual Health Care Conference.BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's chairman and chief executive officer, will present at the Cowen & Co., LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control 27th Annual Health Care Conference, which will begin on March 12, 2007 in Boston, Massachusetts “Boston” redirects here. For other uses, see Boston (disambiguation). Boston is the capital and most populous city of Massachusetts.[3] The largest city in New England, Boston is considered the unofficial economic and cultural center of the entire New . Enzon's presentation will take place at 1:40 p.m. EST P.M. also p.m. or p.m. abbr. post meridiem Usage Note: By definition, 12 a.m. on Monday, March 12, 2007. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon's website at www.enzon.com. About Enzon Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets Abelcet([R]), Oncaspar([R]), Adagen([R]), and Depocyt([R]) in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . In addition, Enzon also receives royalties on sales of PEG-INTRON([R]), marketed by Schering-Plough Corporation, and Macugen([R]), marketed by OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology(TM) PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. The Company also engages in contract manufacturing opportunities with third parties to improve its efficiency. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com. All information in this press release is as of March 6, 2007 and the Company undertakes no duty to update this information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion